FDA regulatory chief to retire; Clean Air violations to cost Pfizer;

> Margaret O'Keefe Glavin, a top U.S. Food and Drug Administration official whose sizeable bonuses were among those criticized by lawmakers last year will retire soon, according to an internal agency memo sent Monday. Report

> Pfizer will pay $975,000 to settle alleged violations of the Clean Air Act at a former manufacturing plant in Groton, Conn. Report

> Novo Nordisk got the FDA nod for PrandiMet, a fixed-dose combination of the fast-acting insulin secretagogue repaglinide and metformin for the treatment of type 2 diabetes. Release

> Unichem Laboratories said it has received FDA approval for its plant in Uttar Pradesh, India; the company makes drug ingredients and some bulk meds. Report

> Orchid Chemicals & Pharmaceuticals won permission from Canadian drug regulators to sell a combination antibiotic piperacillin-tazobactam injection. Report

> Stiefel Laboratories is buying Barrier Therapeutics - a developer of dermatology products - in a deal valued at $148 million. Report

> Seattle-based Immune Design has raised an impressive $18 million in its first round of venture capital. VC report

> BusinessWeek's Gene Marcial sized up BioSante Pharmaceutical's pipeline and concluded that its late stage therapy for sexual dysfunction in menopausal women could make it a prime candidate for a buyout. BioSante report

> British biotech executives are sour on industry's 'dire' shape. Report

> Shares of GTC Therapeutics shot up after the company announced it had inked a $257 million licensing deal with Ovation Pharmaceuticals for its blood clotting therapy ATryn. Report

And Finally... You've heard of drug-resistant germs; now there's drug-resistant high blood pressure. Report